Carbohydrate Or Lignin, Or Derivative Patents (Class 514/777)
-
Publication number: 20130184356Abstract: This invention provides a composition comprising: (i) a chitosan hydrogel comprising cross-linked chitosan and water; and (ii) a liquid dispersed in the hydrogel.Type: ApplicationFiled: April 15, 2011Publication date: July 18, 2013Applicant: VISCOGEL ABInventor: Mats Andersson
-
Publication number: 20130171248Abstract: A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicant: PROCARRIER, INC.Inventors: Seung-Ho Choi, Seong-Wan Cho
-
Patent number: 8475840Abstract: The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 hrs. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels.Type: GrantFiled: April 8, 2005Date of Patent: July 2, 2013Assignee: Hanmi Science Co., LtdInventors: Jong Soo Woo, Hong-Gi Yi, Moon-Hyuk Chi, Jae-Kuk Ryu, Si-Young Jung, Yong-Il Kim
-
Publication number: 20130164335Abstract: Methods and compositions for producing a cellular drug release are disclosed. The method comprises: a) providing a composition comprising a therapeutically effective amount of a pharmacological agent adsorbed onto mesoporous hydroxyapatite (HAP) with hydrophobic surfaces; b) exposing the composition to a cell; c) causing entry of the mesoporous HAP into the cell and degradation of the HAP in the lysosomes of the cell and desorption of the agent from the mesoporous HAP; d) causing release of the desorbed agent from the lysosomes into the cytoplasm of the cell; and e) causing release of the desorbed agent to outside the cell. The composition comprises a) mesoporous HAP with hydrophobic surfaces; and b) a therapeutically effective amount of a pharmacological agent, adsorbed onto the hydrophobic surfaces of the mesoporous. HAP. The composition is characterized in that it constantly releases the agent in vivo for a period of at least 4 weeks.Type: ApplicationFiled: December 27, 2011Publication date: June 27, 2013Applicant: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Cheng CHEN, Feng-Huei Lin
-
Publication number: 20130164311Abstract: A composition of exceptionally dense chitosan and a novel method for producing the dense chitosan structure have been described. The novel production method employs coincident compression and vacuum on a neutralized chitosan polymer that results in an exceptionally dense chitosan film or membrane material. The dense chitosan film or membrane composition possesses multiple physical and clinically appealing qualities for a variety of medical applications on or in animals, mammals, or humans.Type: ApplicationFiled: December 22, 2011Publication date: June 27, 2013Applicant: Agenta Biotechnologies Inc.Inventors: Arthur A. DeCarlo, April Ellis, Thomas P. Dooley, Maria Belousova
-
Publication number: 20130165528Abstract: A disinfectant detergent composition containing a food or food additive as a main component is provided. The disinfectant detergent composition contains the following components (a), (b), and (c). The sum [a+b] of the component (a) content and the component (b) content of the composition ranges from 0.1% to 30% by mass, the mass ratio [a/b] of the component (a) to the component (b) ranges from 1/2 to 4/1, and the component (c) content of the composition ranges from 60% to 99.5% by mass. (a) polyoxyethylene sorbitan monolaurate (b) a fatty acid glyceride in which the number of carbon atoms of its acyl group ranges from 8 to 12, the monoglyceride content of the component (b) being 85% by mass or more, the mass fraction of 1-monoglyceride relative to the total amount of monoglycerides being in the range of 0.9 to 1.0 (c) water and/or ethanol.Type: ApplicationFiled: September 12, 2011Publication date: June 27, 2013Applicant: NOF CORPORATIONInventors: Kazuaki Wakita, Satoko Matani
-
Publication number: 20130158132Abstract: The composition adapted to prolong the residence time of drugs in the circulating plasma of mammals including humans comprises the following: Pectin 0.94 g Potassium bitartrate 0.48 g Tannic acid ?0.8 g L-Tyrosine 0.21 g Riboflavin 2 ml 10% solution of 15% Ethyl Alcohol Hexanoic Acid (Caproic acid) 0.06 ml Ethyl Alcohol 15% Ethyl Alcohol to make 100 ml The composition adapted to prolong the residence time of drugs in the circulating plasma of mammals including humans comprises the following: Pectin 0.94 g Potassium bitartrate 0.48 g Tannic acid ?0.8 g Glutamic acid 0.21 g Riboflavin 2 ml 10% solution of 15% Ethyl Alcohol Hexanoic Acid (Caproic acid) 0.Type: ApplicationFiled: December 19, 2011Publication date: June 20, 2013Inventors: Aida Salatinjants, Robert Salatinjants
-
Publication number: 20130156853Abstract: A liquid composition of an insoluble medicament and a preparation method thereof are disclosed. The composition includes insoluble medicament, oil for injection, phospholipid, and solvent; the percentage by weight of each component is as follows: insoluble medicament 0.01-10%, oil for injection 0%-20%, phospholipid 10-80%, solvent 20-89%. The preparation method for the composition includes the following steps: dissolving an insoluble medicament into solvent or oil for injection or a mixture thereof firstly, and then adding other components, and mixing uniformly; or dissolving an insoluble medicament into a mixture of other components, and mixing uniformly; or dissolving an insoluble medicament into part of solvent firstly, and then adding into a mixed solvent of other components and the remaining solvent, and mixing uniformly.Type: ApplicationFiled: August 31, 2011Publication date: June 20, 2013Applicant: PEKING UNIVERSITYInventors: Qiang Zhang, Wenbing Dai, Jiancheng Wang, Xuan Zhang
-
Publication number: 20130149357Abstract: The present invention discloses a composition comprising a polyelectrolyte complex and a polyol, characterised in that said polyol is in amorphous form. Optionally, the composition further comprises one or more drugs, wherein each drug has a molecular weight of at least 1000 Dalton. Said compositions are obtainable by spray-drying. The compositions may be prepared in particle form and as a suspension of particles. Pharmaceutical compositions are also provided for use in extracellular drug delivery. Pharmaceutical compositions are also provided that exhibit a controlled dual drug release.Type: ApplicationFiled: August 24, 2011Publication date: June 13, 2013Inventors: Jean Paul Remon, Bruno De Geest, Stefaan De Koker, Johan Grooten, Chris Vervaet
-
Publication number: 20130149259Abstract: A novel saccharide siloxane copolymer is useful in personal care compositions. The saccharide siloxane copolymer may be used as a universal emulsifier to prepare low odor emulsions for personal care applications.Type: ApplicationFiled: August 15, 2011Publication date: June 13, 2013Applicant: DOW CORNING CORPORATIONInventors: Cindy Delvalle, Eric Jude Joffre, Concettina Scavuzzo, Simon Toth, Isabelle Van Reeth
-
Publication number: 20130149261Abstract: A saccharide siloxane copolymer is useful as an emulsifier. Emulsions prepared with the saccharide siloxane copolymer are useful in personal care products.Type: ApplicationFiled: August 15, 2011Publication date: June 13, 2013Applicant: DOW CORNING CORPORATIONInventors: Cindy Delvalle, Eric Jude Joffre, Conecttina Scavuzzo, Simon Toth, Isabelle Van Reeth
-
Publication number: 20130149260Abstract: An emulsion contains a saccharide siloxane copolymer as an emulsifier. The emulsion is useful in formulating personal care products.Type: ApplicationFiled: August 15, 2011Publication date: June 13, 2013Applicant: DOW CORNING CORPORATIONInventors: Cindy Delvalle, Eric Jude Joffre, Cinecttina Scavuzzo, Simon Toth, Isabelle Van Reeth
-
Publication number: 20130142731Abstract: This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.Type: ApplicationFiled: January 26, 2011Publication date: June 6, 2013Inventors: Geoffrey C. Gurtner, Jayakumar Rajadas, Kenneth N. Horne, Hiram Chee
-
Publication number: 20130136775Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.Type: ApplicationFiled: November 30, 2011Publication date: May 30, 2013Inventors: Andreas Voigt, Jörg Kriwanek, Scott Hampton, Andreas Reiff, Sonja Ludwig
-
Publication number: 20130137745Abstract: The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.Type: ApplicationFiled: January 22, 2013Publication date: May 30, 2013Applicant: Cumberland Pharmaceuticals Inc.Inventor: Cumberland Pharmaceuticals Inc.
-
Publication number: 20130129825Abstract: The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.Type: ApplicationFiled: June 7, 2011Publication date: May 23, 2013Applicant: EthypharmInventor: Vincent Billoet
-
Publication number: 20130129616Abstract: The invention is a gel composition for delivery to a breast milk duct prior to surgical excision of breast tissue including cancerous lesions. The invention also provides methods of mapping all or nearly all of a breast milk duct prior to surgical excision of breast tissue, and method of identifying part or all of a breast duct or ducts as a surgical aide to a breast surgeon. Kits to support these methods and including these compositions are also provided.Type: ApplicationFiled: October 24, 2012Publication date: May 23, 2013Inventors: Annette Bianchi, Julian Nikolchev, David Hung, Eyal Ron, Linda K. Gont, Susan Love, Tina Patel
-
Publication number: 20130131191Abstract: A disintegrant for tablets includes an ?-1,4-glucan having a degree of polymerization of not less than 180 and less than 1230 and a dispersity (weight average molecular weight “Mw”/number average molecular weight “Mn”) of not more than 1.25 or a modified product thereof. A binder for tablets includes an ?-1,4-glucan having a degree of polymerization of not less than 1230 and not more than 37000 and a dispersity of not more than 1.25, or a modified product thereof. A binding-disintegrating agent for tablets includes a low molecular weight ?-1,4-glucan or a modified product thereof, and a high molecular weight ?-1,4-glucan or a modified product thereof.Type: ApplicationFiled: December 13, 2012Publication date: May 23, 2013Applicants: SANWA CORNSTARCH CO., LTD., EZAKI GLICO CO., LTD.Inventors: EZAKI GLICO CO. LTD., SANWA CORNSTARCH CO., LTD.
-
Publication number: 20130131192Abstract: The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.Type: ApplicationFiled: November 2, 2010Publication date: May 23, 2013Inventors: Jianxin Guo, Anthony Klos, Bret Coldren, Deborah Barnette, Mark Manning
-
Publication number: 20130129800Abstract: The present invention relates to hydrogels based on hyaluronic acid based derivatives, that are more resistant than hyaluronic acid alone towards chemical and enzymatic degradation and are endowed with a mix of chemical and mechanical properties such that they are of optimal use in several surgeries, for instance for injection in bone fractures or cavities and for the production of coatings of prostheses in orthopedic surgery, as fillers in cosmetic and maxillo-facial surgery, as anti-adhesion barrier in the prevention of postoperative adhesions in abdominal and abdominal/pelvic surgery, and in general surgery. These hydrogels can be loaded with several different kinds of compounds having pharmacological and biological activity, that are then released from the hydrogel in the site of intervention.Type: ApplicationFiled: July 29, 2011Publication date: May 23, 2013Applicants: MERO S.R.L., NOVAGENIT S.R.LInventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano', Enzo Meani, Edgardo Cremascoli
-
Publication number: 20130129801Abstract: A method for preparing a dispersion of polar lipids in an ethanol-water mixture, the polar lipids including galactolipids. Anoil containing polar lipids including galactolipids is diluted using a first ethanol-water mixture having an ethanol concentration close to the critical polarity, wherein upon dilution the polar lipids form a lamellar liquid-crystalline phase, without first forming a hexagonal HII-phase. The invention also refers to an oil obtained by evaporating ethanol and water from the dispersion. The invention further refers to aqueous colloidal dispersions of polar lipids including galactolipids, to an oil containing polar lipids including galactolipids and to pharmaceutical, cosmetic and food compositions including such dispersions and/or oil.Type: ApplicationFiled: May 24, 2011Publication date: May 23, 2013Applicant: SWEDISH OAT FIBER ABInventors: Kare Larsson, Magnus Harrod
-
Patent number: 8445427Abstract: The invention provides a method for selecting and eliminating endotoxin selectively from a solution where a highly acidic substance such as heparin co-exists, and an adsorbent used therefore. The invention also provides a method for providing the endotoxin adsorbent, which includes partially modifying amino groups contained within an amino group-containing molecule used as a ligand of the endotoxin adsorbent, with a molecule that is capable of reacting with an amino group.Type: GrantFiled: November 22, 2006Date of Patent: May 21, 2013Assignee: JNC CorporationInventors: Minoru Nakayama, Masami Todokoro
-
Publication number: 20130123180Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises inulin.Type: ApplicationFiled: March 28, 2011Publication date: May 16, 2013Applicant: FERRING B.V.Inventors: Varinder Ahuja, Tejas Gunjikar, Kristin Wannerberger
-
Publication number: 20130121938Abstract: Disclosed is an oil-in-water emulsion comprising about 2-3% w/w of a combination of glyceryl stearate, arachidyl alcohol, PEG-100 stearate, and arachidyl glucoside.Type: ApplicationFiled: December 28, 2012Publication date: May 16, 2013Applicant: MARY KAY INC.Inventor: Mary Kay Inc.
-
Publication number: 20130122073Abstract: The invention relates to a composition, particularly in the form of liquid to be used externally as a rinsing contact lenses, containing nanocrystalline photocatalyst active in visible light, and optionally hydrogen peroxide.Type: ApplicationFiled: April 23, 2011Publication date: May 16, 2013Applicant: UNIWERSYTET JAGIELLONSKIInventors: Przemyslaw Labuz, Wojchiech Maccyk, Grazyna Stochel, Piotr Heczko, Magdalena Strus
-
Publication number: 20130123179Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.Type: ApplicationFiled: March 28, 2011Publication date: May 16, 2013Applicant: FERRING B.V.Inventors: Shweta Gupta, Varinder Ahuja, Tejas Gunjikar, Kristin Wannerberger
-
Publication number: 20130115268Abstract: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.Type: ApplicationFiled: December 27, 2012Publication date: May 9, 2013Applicants: TEIKIKOKU SEIYAKU KABUSHIKI KAISHA, TEIKOKU PHARMA USA, INC.Inventors: Teikoku Pharma USA, INC., Teikikoku Seiyaku Kabushiki Kaisha
-
Patent number: 8435555Abstract: A method of preparing a salt product comprises the steps of: (i) providing a mixture which comprises salt dissolved in a solvent, said mixture further containing an organic material that is solid under ambient temperature conditions; and (ii) atomising said mixture and evaporating said solvent to produce a salt product comprised of particles of salt incorporating said organic material. The organic material may be a polymer such as a carbohydrate (e.g. maltodextrin or Gum Arabic). Novel salt products are disclosed which comprise hollow particles having a shell formed for individual crystallites of salt. The salt product is useful as a seasoning for food and may be used in lower amounts than conventional salt to provide the same taste. Particular advantages are obtained in the baking of bread.Type: GrantFiled: May 1, 2009Date of Patent: May 7, 2013Assignee: Eminate LimitedInventors: Stephen John Minter, Sarah Maude
-
Publication number: 20130102545Abstract: The present invention relates to an active substance release system containing two compounds. The first compound comprises a nanoparticle, combined with an oligonucleotide inhibition strand that is hybridized with a catalytically active nucleic acid. The second compound comprises a carrier, combined with a substrate molecule that is coupled to a therapeutic active substance. By means of external stimulation, the catalytically active nucleic acid of the first compound is released and specifically binds to the substrate molecule of the second compound. This leads to cleavage of the substrate molecule, whereby the active substance bound thereto is released.Type: ApplicationFiled: December 16, 2010Publication date: April 25, 2013Inventors: Jiang Gao, Monika Fischler, Volker A. Erdmann
-
Publication number: 20130101684Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.Type: ApplicationFiled: April 15, 2011Publication date: April 25, 2013Applicant: Chromocell CorporationInventors: Jane V. Leland, Louise Slade, David Hayashi, William P. Jones, Peter H. Brown, Joseph Gunnet, Daniel Lavery, Jessica Langer, Kambiz Shekdar
-
Publication number: 20130098550Abstract: A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry.Type: ApplicationFiled: March 24, 2011Publication date: April 25, 2013Applicant: COVIDIEN LPInventors: Tim Sargeant, Robert Ahmad Hadba, Joshua Stopek
-
Publication number: 20130096207Abstract: Provided is a water dispersion type sex pheromone sustained release preparation which makes it possible to suppress excess release at the initial stage of spraying and release a sex pheromone substance at a constant amount for a predetermined period, and which can be sprayed by using a common sprayer. Specifically provided is a water dispersion type sex pheromone sustained release preparation, comprising an insect sex pheromone substance which is enclosed in a ring of a cyclodextrin, an inclusion cyclodextrin which encloses the insect sex pheromone substance, a non-inclusion cyclodextrin which does not enclose the insect sex pheromone substance, a water-soluble polymer, and water.Type: ApplicationFiled: October 2, 2012Publication date: April 18, 2013Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventor: Shin-Etsu Chemical Co., Ltd.
-
Publication number: 20130089592Abstract: The invention provides a method of enzymatically modifying xylan by selectively removing glucuronic acid and/or arabinose side chains from the xylan with a-D-glucuronidase and/or a-L-arabinofuranosidase, and allowing the modified xylan to form into a hydrogel when the xylan becomes insoluble. A bioactive substance, such as a protein, enzyme, antimicrobial agent, bactericide or pharmaceutical compound can be added to the xylan so that the substance is encapsulated within the hydrogel or incorporated onto its surface. The hydrogel can be used as a drug delivery agent, such as for sustained-release or targeted drug delivery, rectal drug delivery or a dressing for a wound, burn or scar. The hydrogel can also be used as a coating, such as on medical gloves, catheters, surgical drainage systems, utensils or the like, or can be used in a scaffold for tissue engineering.Type: ApplicationFiled: June 7, 2011Publication date: April 11, 2013Applicant: STELLENBOSCH UNIVERSITYInventors: Willem Heber Van Zyl, Annie Fabian Abel Chimphango, Johann Ferdinand Gorgens
-
Publication number: 20130090237Abstract: In one embodiment, a method includes making a pteredin phenyl pentanedioic (3P) formulation by providing an aqueous solution including one of more 3P molecules neutralized with one or more of an alkali, an alkali earth metal hydroxide, or an alkali carbonate; adding to the aqueous solution one of a surfactant, dispersant, or additive with the guest molecules; and non-covalently crosslinking the 3P formulation by exposing the 3P formulation to an excess solution of multivalent cation salt.Type: ApplicationFiled: October 11, 2011Publication date: April 11, 2013Inventor: Sanat Mohanty
-
Publication number: 20130090240Abstract: The present invention provides the efficacy-enhancing agent composition for agricultural chemicals containing (A) the sorbitan fatty acid ester surfactant, (B) the rosin-oxyalkylene adduct surfactant or a specified quaternary ammonium salt surfactant, and (C) a specified glycol ether solvent.Type: ApplicationFiled: July 11, 2011Publication date: April 11, 2013Applicant: KAO CORPORATIONInventors: Katsuhiko Yamaguchi, Kazuhiko Kurita
-
Patent number: 8415401Abstract: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.Type: GrantFiled: December 5, 2008Date of Patent: April 9, 2013Assignee: Durect CorporationInventors: Su Il Yum, Wendy Chao, Huey-Ching Su, Roger Fu, Michael Zamloot
-
Publication number: 20130084265Abstract: A controlled release delivery system composition and method applied to humans and animals, for oral, anal or vaginal administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature, however, the biological component is not limited to the bacterium.Type: ApplicationFiled: November 27, 2012Publication date: April 4, 2013Applicant: TNTGAMBLE, INC.Inventor: TNTGamble, Inc.
-
Publication number: 20130085187Abstract: The present disclosure relates to a deacetylation hydrolase of a hyaluronic acid a hyaluronic acid deacetylated by same and a derivative thereof. The deacetylated hyaluronic acid and the derivative thereof have the following characteristic: a delayed initial decomposition rate on a living body; minimized decrease of molecular weight and viscosity; accelerated gelation due to a lower gelation temperature than the gelation temperature for a non-deacetylated hyaluronic acid; and an hMSC survival rate that is hardly affected by increased concentration of the deacetylated hyaluronic acid and the derivative thereof in a culture medium. As a result, the deacetylated hyaluronic acid and the derivative thereof can be useful as a bioingredient such a delivery system for a cell, gene, drug, and the like, or a support for tissue engineering, etc.Type: ApplicationFiled: June 10, 2011Publication date: April 4, 2013Applicant: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCESInventors: Chun-Ho Kim, Jong-Il Kim
-
Patent number: 8409621Abstract: A method of forming particles, comprises accelerating a first stream comprising a first liquid, applying a charging voltage of at most 1.5 kV to the first stream, and vibrating the first stream, to form particles.Type: GrantFiled: November 13, 2007Date of Patent: April 2, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Kyekyoon Kim, Hyungsoo Choi, Young Bin Choy
-
Patent number: 8409610Abstract: A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound.Type: GrantFiled: September 12, 2011Date of Patent: April 2, 2013Assignee: Coloplast A/SInventors: Gitte Juel Friis, Truels Sterm Larsen
-
Publication number: 20130079422Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.Type: ApplicationFiled: November 16, 2012Publication date: March 28, 2013Applicant: FXS Ventures, LLCInventor: FXS Ventures, LLC
-
Publication number: 20130078285Abstract: Mono- and multi-layered implants include at least one porous layer made from a freeze dried aqueous solution containing chitosan, the solution having a pH of less than about 5.Type: ApplicationFiled: March 28, 2011Publication date: March 28, 2013Applicant: SOFRADIM PRODUCTIONInventors: Sébastien Ladet, Julien Claret
-
Publication number: 20130078299Abstract: Crosslinked hydrogel-based transdermal pharmaceutical formulations. The hydrogel transdermal formulations. Transdermal patches are useful for administering a variety of drugs to patients. The transdermal patches here employ crosslinked-hydrogels generated through irradiation, thus eliminating any residual effects associated with chemical- or UV-based crosslinking procedures. The transdermal patches may be formed from a variety of high-molecular weight polymeric compounds and include substantial levels of water to improve skin tolerance by the patient. The transdermal patches may also include transcutol as a solvent for the drug, which has been found to increase the effectiveness of drug delivery. The present disclosure also provides for methods of loading a drug into a transdermal formulation after the crosslinking of the hydrogel, thus improving stability and bioavailability through avoiding exposure of the drug to the radiation used in the crosslinking procedure.Type: ApplicationFiled: April 11, 2012Publication date: March 28, 2013Applicant: Alliqua, Inc.Inventors: Matthew HARRITON, Gregory Robb, Ronald S. Harland
-
Publication number: 20130072578Abstract: Erythritol is granulated together with at least 10% w/w isomalt. Prior and/or after granulation a disintegrant is added and orodispersible tablets are prepared. The tablet has a disintegration time of less than 100 seconds, less than 90 seconds, preferably less than 80 seconds, more preferably less than 60 seconds and said disintegration time was determined according to the European Pharmacopoeia VI, Test method 2.9.1 by using a pharmaceutical disintegration tester model ZT 73 whereby 6 tablets having a surface of 1 square centimeter and a weight of 350 mg, at a compression force of 20 kN, were analyzed and mean values were calculated. The process for preparing the orodispersible tablet, its use, and the intermediate granulate are described as well.Type: ApplicationFiled: May 17, 2011Publication date: March 21, 2013Inventors: Catherine Patricia L. Boghmans, Liesbeth Maria Fernande Meeus
-
Publication number: 20130071339Abstract: Methods of preparing highly purified steviol glycosides, particularly Rebaudioside D, are described. The methods include purification from the extraction stage of the Stevia rebaudiana Bertoni plant, purification of steviol glycoside mixtures, Rebaudioside D and Rebaudioside A from a commercial Stevia extract, and purification of Rebaudioside D from remaining solutions obtained after isolation and purification of Rebaudioside A and a high purity mixture of steviol glycosides. The methods are useful for producing high purity Rebaudioside D, Rebaudioside A, and steviol glycoside mixtures. The high purity steviol glycosides are useful as non-caloric sweeteners in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.Type: ApplicationFiled: March 11, 2011Publication date: March 21, 2013Inventor: Avetik Markosyan
-
Publication number: 20130064782Abstract: The subject of the invention is the use of an extract of Stevia in combination with a salt, for masking the bitterness of bitter compounds in cosmetic or dermatological compositions. This mixture of sweetener with a second gustatory agent makes it possible to mask the bitterness of the compound permanently without changing the nature of the fragrance or the colour of the composition.Type: ApplicationFiled: August 31, 2012Publication date: March 14, 2013Applicant: LVMH RECHERCHEInventors: Karine CHEVET, Valerie ALARD, Eric PERRIER, Marie-Laure SOUVIE
-
Publication number: 20130058882Abstract: A personal care composition which has an ethylenic monomer having a molecular weight of 500 g/mole or less and a compound selected from the group consisting of 2-tert-butyl-4-hydroxy-anisole, 3-tert-butyl-4-hydroxy-anisole, and mixtures thereof. The compound is present in the personal care composition in an amount of from about 1 milligram to about 1000 milligram per kilogram of the ethylenic monomer.Type: ApplicationFiled: August 30, 2012Publication date: March 7, 2013Inventors: Andreas FLOHR, Thomas Kripp, Curtis Bobby Motley
-
Publication number: 20130059769Abstract: The present invention relates to topical glycosaminoglycan compositions, particularly hyaluronan compositions, that facilitate the penetration of modified glycosaminoglycans through the skin barrier into the epidermal and dermal layers of the skin, thereby allowing for the dermal administration of a glycosaminoglycan, such as hyaluronan, without requiring an injection. Through their ability to deliver hyaluronan to the epidermal and dermal layers, the present formulations are therefore suitable for use in dermal rejuvenation, enhancement, hyaluronan replenishment and protection therapy. The glycosaminoglycan compositions are also useful as delivery devices to facilitate the dermal and transdermal delivery of cosmetically and pharmaceutically active substances, including pharmaceuticals, polypeptides, proteins and similarly sized biomacromolecules, through the skin barrier.Type: ApplicationFiled: May 4, 2011Publication date: March 7, 2013Inventor: Eva Turley
-
Publication number: 20130053453Abstract: The present invention relates to a novel dermal filler composition and a method for preparing the same. Even though the composition of the present invention comprises, as a main component, only cross-linked dextran having the molecular weight of 30,000 to 100,000, the composition can rapidly augment a detective area of the skin and maintain softness to the touch even, the composition eliminates the necessity of a pretreatment, such as an allergy test, which might otherwise be required prior to injection, is inexpensive, and is not easily decomposed or absorbed in vivo, thereby stably maintaining the tissue-volume augmentation effects after injection over a long period of time.Type: ApplicationFiled: March 7, 2011Publication date: February 28, 2013Inventor: Kang Seon Jo
-
Publication number: 20130046028Abstract: A cosmetic raw material comprising the following components (A), (B), and (C): (A) a specific polyether-modified organopolysiloxane; (B) a chain-form silicone oil that is a liquid at 25° C., does not contain a cyclic structure, and does not contain a resinous structure; and (C) an oil that is a liquid at 30° C. and that characteristically (c1) has at least one hydroxyl group in each molecule, (c2) has from 0 to 3, as the number of moles of addition, oxyethylene units in each molecule, (c3) has an HLB value in the range from 0.1 to 6.0, and (c4) has an average molecular weight in the range from 200 to 7000.Type: ApplicationFiled: April 28, 2011Publication date: February 21, 2013Applicants: DOW CORNING TORAY CO., LTD., DOW CORNING CORPORATIONInventors: Brian P. Deeth, Haruhiko Furukawa, Tatsuo Souda, Seiki Tamura